Global Neisseria Gonorrhoeae Infections Treatment

Neisseria Gonorrhoeae Infections Treatment Comprehensive Study by Type (Cribrostatin-6 , Dalbavancin , Debio-1453 , Gepotidacin Mesylate , Others), Patient Type (Gonorrhea treatment in adults, Gonorrhea treatment for partners, Gonorrhea treatment for babies), Drugs (Erythromycin, Clarithromycin, Azithromycin, Roxithromycin, Others), Adminstration (Oral, Injectable), End User (Clinic , Hospital , Others) Players and Region - Global Market Outlook to 2025

Neisseria Gonorrhoeae Infections Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Neisseria Gonorrhoeae Infections Treatment Market?

Neisseria Gonorrhoeae Infections is the second most prevalent bacterial sexually transmitted infection globally and remains an important clinical and public health problem throughout the world. According to the research in the year 2016, an estimated 87 million new cases of gonorrhea occurred. Sexually transmitted diseases are a significant general medical issue around the world, influencing personal satisfaction and causing genuine horribleness and mortality. Sexually transmitted infections have a direct impact on reproductive and child health through infertility, cancers, and pregnancy complications, and they have an indirect impact through their role in facilitating sexual transmission of the human immunodeficiency virus (HIV) and thus they also have an impact on national and individual economies. More than a million.Sexually transmitted diseases are acquired every day. y.The rising prevalence of gonorrhea worldwide is driving the growth of this market Huge financial support to the researchers for developing novel intervention is boosting the market growth High demand for disease-specific novel treatment can also act as a market driver Increase in incidence of unprotected sex has led to an increase in the prevalence gonorrhea can propel the growth of this market.

The market study is being classified by Type (Cribrostatin-6 , Dalbavancin , Debio-1453 , Gepotidacin Mesylate  and Others) and major geographies with country level break-up.

Allergan Plc (Ireland), BioDiem Ltd (Australia), Debiopharm International SA (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline Plc (United Kingdom), Merck & Co., Inc. (United States), Paratek Pharmaceuticals, Inc. (United States), Recce Pty Ltd (Australia) and Redx Pharma Plc (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sarepta Therapeutics, Inc. (United States) and Sumitomo Dainippon Pharma Co., Ltd (Japan).

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Neisseria Gonorrhoeae Infections Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Neisseria Gonorrhoeae Infections Treatment market by Type, Application and Region.

On the basis of geography, the market of Neisseria Gonorrhoeae Infections Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing gonorrhea prevalence
  • The rise in the incidence of unprotected sex has led to an increase in the prevalence of gonorrhea

Market Trend
  • Rise in the number of insurance payers,

Restraints
  • High cost associated with the treatment Neisseria Gonorrhoeae Infections Treatment in rural area

Opportunities
  • Increase in the patient population of Neisseria Gonorrhoeae Infections Treatment

Challenges
  • Lack of awareness regarding


In October 2019GlaxoSmithKline plc announced that patient dosing has begun in phase III clinical program investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection (UTI, also known as acute cystitis) and urogenital gonorrhea (GC).


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Neisseria Gonorrhoeae Infections Treatment Manufacturer, Neisseria Gonorrhoeae Infections Treatment Suppliers, Government Regulatory and Research Organizations and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • Cribrostatin-6 
  • Dalbavancin 
  • Debio-1453 
  • Gepotidacin Mesylate 
  • Others
By Patient Type
  • Gonorrhea treatment in adults
  • Gonorrhea treatment for partners
  • Gonorrhea treatment for babies

By Drugs
  • Erythromycin
  • Clarithromycin
  • Azithromycin
  • Roxithromycin
  • Others

By Adminstration
  • Oral
  • Injectable

By End User
  • Clinic 
  • Hospital 
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing gonorrhea prevalence
      • 3.2.2. The rise in the incidence of unprotected sex has led to an increase in the prevalence of gonorrhea
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness regarding
    • 3.4. Market Trends
      • 3.4.1. Rise in the number of insurance payers,
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neisseria Gonorrhoeae Infections Treatment, by Type, Patient Type, Drugs, Adminstration, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neisseria Gonorrhoeae Infections Treatment (Value)
      • 5.2.1. Global Neisseria Gonorrhoeae Infections Treatment by: Type (Value)
        • 5.2.1.1. Cribrostatin-6 
        • 5.2.1.2. Dalbavancin 
        • 5.2.1.3. Debio-1453 
        • 5.2.1.4. Gepotidacin Mesylate 
        • 5.2.1.5. Others
      • 5.2.2. Global Neisseria Gonorrhoeae Infections Treatment by: Patient Type (Value)
        • 5.2.2.1. Gonorrhea treatment in adults
        • 5.2.2.2. Gonorrhea treatment for partners
        • 5.2.2.3. Gonorrhea treatment for babies
      • 5.2.3. Global Neisseria Gonorrhoeae Infections Treatment by: Drugs (Value)
        • 5.2.3.1. Erythromycin
        • 5.2.3.2. Clarithromycin
        • 5.2.3.3. Azithromycin
        • 5.2.3.4. Roxithromycin
        • 5.2.3.5. Others
      • 5.2.4. Global Neisseria Gonorrhoeae Infections Treatment by: Adminstration (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Injectable
      • 5.2.5. Global Neisseria Gonorrhoeae Infections Treatment by: End User (Value)
        • 5.2.5.1. Clinic 
        • 5.2.5.2. Hospital 
        • 5.2.5.3. Others
      • 5.2.6. Global Neisseria Gonorrhoeae Infections Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Neisseria Gonorrhoeae Infections Treatment (Volume)
      • 5.3.1. Global Neisseria Gonorrhoeae Infections Treatment by: Type (Volume)
        • 5.3.1.1. Cribrostatin-6 
        • 5.3.1.2. Dalbavancin 
        • 5.3.1.3. Debio-1453 
        • 5.3.1.4. Gepotidacin Mesylate 
        • 5.3.1.5. Others
      • 5.3.2. Global Neisseria Gonorrhoeae Infections Treatment by: Patient Type (Volume)
        • 5.3.2.1. Gonorrhea treatment in adults
        • 5.3.2.2. Gonorrhea treatment for partners
        • 5.3.2.3. Gonorrhea treatment for babies
      • 5.3.3. Global Neisseria Gonorrhoeae Infections Treatment by: Drugs (Volume)
        • 5.3.3.1. Erythromycin
        • 5.3.3.2. Clarithromycin
        • 5.3.3.3. Azithromycin
        • 5.3.3.4. Roxithromycin
        • 5.3.3.5. Others
      • 5.3.4. Global Neisseria Gonorrhoeae Infections Treatment by: Adminstration (Volume)
        • 5.3.4.1. Oral
        • 5.3.4.2. Injectable
      • 5.3.5. Global Neisseria Gonorrhoeae Infections Treatment by: End User (Volume)
        • 5.3.5.1. Clinic 
        • 5.3.5.2. Hospital 
        • 5.3.5.3. Others
      • 5.3.6. Global Neisseria Gonorrhoeae Infections Treatment Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Neisseria Gonorrhoeae Infections Treatment (Price)
      • 5.4.1. Global Neisseria Gonorrhoeae Infections Treatment by: Type (Price)
  • 6. Neisseria Gonorrhoeae Infections Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan Plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioDiem Ltd (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Debiopharm International SA (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Paratek Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Recce Pty Ltd (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Redx Pharma Plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Neisseria Gonorrhoeae Infections Treatment Sale, by Type, Patient Type, Drugs, Adminstration, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neisseria Gonorrhoeae Infections Treatment (Value)
      • 7.2.1. Global Neisseria Gonorrhoeae Infections Treatment by: Type (Value)
        • 7.2.1.1. Cribrostatin-6 
        • 7.2.1.2. Dalbavancin 
        • 7.2.1.3. Debio-1453 
        • 7.2.1.4. Gepotidacin Mesylate 
        • 7.2.1.5. Others
      • 7.2.2. Global Neisseria Gonorrhoeae Infections Treatment by: Patient Type (Value)
        • 7.2.2.1. Gonorrhea treatment in adults
        • 7.2.2.2. Gonorrhea treatment for partners
        • 7.2.2.3. Gonorrhea treatment for babies
      • 7.2.3. Global Neisseria Gonorrhoeae Infections Treatment by: Drugs (Value)
        • 7.2.3.1. Erythromycin
        • 7.2.3.2. Clarithromycin
        • 7.2.3.3. Azithromycin
        • 7.2.3.4. Roxithromycin
        • 7.2.3.5. Others
      • 7.2.4. Global Neisseria Gonorrhoeae Infections Treatment by: Adminstration (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Injectable
      • 7.2.5. Global Neisseria Gonorrhoeae Infections Treatment by: End User (Value)
        • 7.2.5.1. Clinic 
        • 7.2.5.2. Hospital 
        • 7.2.5.3. Others
      • 7.2.6. Global Neisseria Gonorrhoeae Infections Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Neisseria Gonorrhoeae Infections Treatment (Volume)
      • 7.3.1. Global Neisseria Gonorrhoeae Infections Treatment by: Type (Volume)
        • 7.3.1.1. Cribrostatin-6 
        • 7.3.1.2. Dalbavancin 
        • 7.3.1.3. Debio-1453 
        • 7.3.1.4. Gepotidacin Mesylate 
        • 7.3.1.5. Others
      • 7.3.2. Global Neisseria Gonorrhoeae Infections Treatment by: Patient Type (Volume)
        • 7.3.2.1. Gonorrhea treatment in adults
        • 7.3.2.2. Gonorrhea treatment for partners
        • 7.3.2.3. Gonorrhea treatment for babies
      • 7.3.3. Global Neisseria Gonorrhoeae Infections Treatment by: Drugs (Volume)
        • 7.3.3.1. Erythromycin
        • 7.3.3.2. Clarithromycin
        • 7.3.3.3. Azithromycin
        • 7.3.3.4. Roxithromycin
        • 7.3.3.5. Others
      • 7.3.4. Global Neisseria Gonorrhoeae Infections Treatment by: Adminstration (Volume)
        • 7.3.4.1. Oral
        • 7.3.4.2. Injectable
      • 7.3.5. Global Neisseria Gonorrhoeae Infections Treatment by: End User (Volume)
        • 7.3.5.1. Clinic 
        • 7.3.5.2. Hospital 
        • 7.3.5.3. Others
      • 7.3.6. Global Neisseria Gonorrhoeae Infections Treatment Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Neisseria Gonorrhoeae Infections Treatment (Price)
      • 7.4.1. Global Neisseria Gonorrhoeae Infections Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neisseria Gonorrhoeae Infections Treatment: by Type(USD Million)
  • Table 2. Neisseria Gonorrhoeae Infections Treatment Cribrostatin-6  , by Region USD Million (2015-2020)
  • Table 3. Neisseria Gonorrhoeae Infections Treatment Dalbavancin  , by Region USD Million (2015-2020)
  • Table 4. Neisseria Gonorrhoeae Infections Treatment Debio-1453  , by Region USD Million (2015-2020)
  • Table 5. Neisseria Gonorrhoeae Infections Treatment Gepotidacin Mesylate  , by Region USD Million (2015-2020)
  • Table 6. Neisseria Gonorrhoeae Infections Treatment Others , by Region USD Million (2015-2020)
  • Table 7. Neisseria Gonorrhoeae Infections Treatment: by Patient Type(USD Million)
  • Table 8. Neisseria Gonorrhoeae Infections Treatment Gonorrhea treatment in adults , by Region USD Million (2015-2020)
  • Table 9. Neisseria Gonorrhoeae Infections Treatment Gonorrhea treatment for partners , by Region USD Million (2015-2020)
  • Table 10. Neisseria Gonorrhoeae Infections Treatment Gonorrhea treatment for babies , by Region USD Million (2015-2020)
  • Table 11. Neisseria Gonorrhoeae Infections Treatment: by Drugs(USD Million)
  • Table 12. Neisseria Gonorrhoeae Infections Treatment Erythromycin , by Region USD Million (2015-2020)
  • Table 13. Neisseria Gonorrhoeae Infections Treatment Clarithromycin , by Region USD Million (2015-2020)
  • Table 14. Neisseria Gonorrhoeae Infections Treatment Azithromycin , by Region USD Million (2015-2020)
  • Table 15. Neisseria Gonorrhoeae Infections Treatment Roxithromycin , by Region USD Million (2015-2020)
  • Table 16. Neisseria Gonorrhoeae Infections Treatment Others , by Region USD Million (2015-2020)
  • Table 17. Neisseria Gonorrhoeae Infections Treatment: by Adminstration(USD Million)
  • Table 18. Neisseria Gonorrhoeae Infections Treatment Oral , by Region USD Million (2015-2020)
  • Table 19. Neisseria Gonorrhoeae Infections Treatment Injectable , by Region USD Million (2015-2020)
  • Table 20. Neisseria Gonorrhoeae Infections Treatment: by End User(USD Million)
  • Table 21. Neisseria Gonorrhoeae Infections Treatment Clinic  , by Region USD Million (2015-2020)
  • Table 22. Neisseria Gonorrhoeae Infections Treatment Hospital  , by Region USD Million (2015-2020)
  • Table 23. Neisseria Gonorrhoeae Infections Treatment Others , by Region USD Million (2015-2020)
  • Table 24. South America Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2015-2020)
  • Table 25. South America Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 26. South America Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 27. South America Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 28. South America Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 29. South America Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 30. Brazil Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 31. Brazil Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 32. Brazil Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 33. Brazil Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 34. Brazil Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 35. Argentina Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 36. Argentina Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 37. Argentina Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 38. Argentina Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 39. Argentina Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 40. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 41. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 42. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 43. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 44. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 45. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2015-2020)
  • Table 46. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 47. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 48. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 49. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 50. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 51. China Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 52. China Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 53. China Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 54. China Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 55. China Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 56. Japan Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 57. Japan Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 58. Japan Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 59. Japan Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 60. Japan Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 61. India Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 62. India Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 63. India Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 64. India Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 65. India Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 66. South Korea Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 67. South Korea Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 68. South Korea Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 69. South Korea Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 70. South Korea Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 71. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 72. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 73. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 74. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 75. Taiwan Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 76. Australia Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 77. Australia Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 78. Australia Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 79. Australia Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 80. Australia Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 86. Europe Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2015-2020)
  • Table 87. Europe Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 88. Europe Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 89. Europe Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 90. Europe Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 91. Europe Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 92. Germany Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 93. Germany Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 94. Germany Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 95. Germany Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 96. Germany Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 97. France Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 98. France Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 99. France Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 100. France Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 101. France Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 102. Italy Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 103. Italy Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 104. Italy Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 105. Italy Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 106. Italy Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 107. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 108. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 109. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 110. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 111. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 112. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 113. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 114. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 115. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 116. Netherlands Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 117. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 118. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 119. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 120. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 121. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 122. MEA Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2015-2020)
  • Table 123. MEA Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 124. MEA Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 125. MEA Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 126. MEA Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 127. MEA Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 128. Middle East Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 129. Middle East Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 130. Middle East Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 131. Middle East Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 132. Middle East Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 133. Africa Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 134. Africa Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 135. Africa Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 136. Africa Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 137. Africa Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 138. North America Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2015-2020)
  • Table 139. North America Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 140. North America Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 141. North America Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 142. North America Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 143. North America Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 144. United States Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 145. United States Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 146. United States Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 147. United States Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 148. United States Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 149. Canada Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 150. Canada Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 151. Canada Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 152. Canada Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 153. Canada Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 154. Mexico Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2015-2020)
  • Table 155. Mexico Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2015-2020)
  • Table 156. Mexico Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2015-2020)
  • Table 157. Mexico Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2015-2020)
  • Table 158. Mexico Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2015-2020)
  • Table 159. Neisseria Gonorrhoeae Infections Treatment Sales: by Type(K Tons)
  • Table 160. Neisseria Gonorrhoeae Infections Treatment Sales Cribrostatin-6  , by Region K Tons (2015-2020)
  • Table 161. Neisseria Gonorrhoeae Infections Treatment Sales Dalbavancin  , by Region K Tons (2015-2020)
  • Table 162. Neisseria Gonorrhoeae Infections Treatment Sales Debio-1453  , by Region K Tons (2015-2020)
  • Table 163. Neisseria Gonorrhoeae Infections Treatment Sales Gepotidacin Mesylate  , by Region K Tons (2015-2020)
  • Table 164. Neisseria Gonorrhoeae Infections Treatment Sales Others , by Region K Tons (2015-2020)
  • Table 165. Neisseria Gonorrhoeae Infections Treatment Sales: by Patient Type(K Tons)
  • Table 166. Neisseria Gonorrhoeae Infections Treatment Sales Gonorrhea treatment in adults , by Region K Tons (2015-2020)
  • Table 167. Neisseria Gonorrhoeae Infections Treatment Sales Gonorrhea treatment for partners , by Region K Tons (2015-2020)
  • Table 168. Neisseria Gonorrhoeae Infections Treatment Sales Gonorrhea treatment for babies , by Region K Tons (2015-2020)
  • Table 169. Neisseria Gonorrhoeae Infections Treatment Sales: by Drugs(K Tons)
  • Table 170. Neisseria Gonorrhoeae Infections Treatment Sales Erythromycin , by Region K Tons (2015-2020)
  • Table 171. Neisseria Gonorrhoeae Infections Treatment Sales Clarithromycin , by Region K Tons (2015-2020)
  • Table 172. Neisseria Gonorrhoeae Infections Treatment Sales Azithromycin , by Region K Tons (2015-2020)
  • Table 173. Neisseria Gonorrhoeae Infections Treatment Sales Roxithromycin , by Region K Tons (2015-2020)
  • Table 174. Neisseria Gonorrhoeae Infections Treatment Sales Others , by Region K Tons (2015-2020)
  • Table 175. Neisseria Gonorrhoeae Infections Treatment Sales: by Adminstration(K Tons)
  • Table 176. Neisseria Gonorrhoeae Infections Treatment Sales Oral , by Region K Tons (2015-2020)
  • Table 177. Neisseria Gonorrhoeae Infections Treatment Sales Injectable , by Region K Tons (2015-2020)
  • Table 178. Neisseria Gonorrhoeae Infections Treatment Sales: by End User(K Tons)
  • Table 179. Neisseria Gonorrhoeae Infections Treatment Sales Clinic  , by Region K Tons (2015-2020)
  • Table 180. Neisseria Gonorrhoeae Infections Treatment Sales Hospital  , by Region K Tons (2015-2020)
  • Table 181. Neisseria Gonorrhoeae Infections Treatment Sales Others , by Region K Tons (2015-2020)
  • Table 182. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2015-2020)
  • Table 183. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 184. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 185. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 186. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 187. South America Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 188. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 189. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 190. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 191. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 192. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 193. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 194. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 195. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 196. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 197. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 198. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 199. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 200. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 201. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 202. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 203. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2015-2020)
  • Table 204. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 205. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 206. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 207. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 208. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 209. China Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 210. China Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 211. China Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 212. China Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 213. China Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 214. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 215. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 216. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 217. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 218. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 219. India Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 220. India Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 221. India Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 222. India Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 223. India Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 224. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 225. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 226. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 227. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 228. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 229. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 230. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 231. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 232. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 233. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 234. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 235. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 236. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 237. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 238. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 239. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 240. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 241. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 242. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 243. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 244. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2015-2020)
  • Table 245. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 246. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 247. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 248. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 249. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 250. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 251. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 252. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 253. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 254. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 255. France Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 256. France Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 257. France Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 258. France Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 259. France Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 260. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 261. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 262. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 263. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 264. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 265. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 266. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 267. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 268. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 269. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 270. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 271. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 272. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 273. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 274. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 275. Rest of Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 276. Rest of Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 277. Rest of Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 278. Rest of Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 279. Rest of Europe Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 280. MEA Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2015-2020)
  • Table 281. MEA Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 282. MEA Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 283. MEA Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 284. MEA Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 285. MEA Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 286. Middle East Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 287. Middle East Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 288. Middle East Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 289. Middle East Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 290. Middle East Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 291. Africa Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 292. Africa Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 293. Africa Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 294. Africa Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 295. Africa Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 296. North America Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2015-2020)
  • Table 297. North America Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 298. North America Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 299. North America Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 300. North America Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 301. North America Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 302. United States Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 303. United States Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 304. United States Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 305. United States Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 306. United States Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 307. Canada Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 308. Canada Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 309. Canada Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 310. Canada Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 311. Canada Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 312. Mexico Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2015-2020)
  • Table 313. Mexico Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2015-2020)
  • Table 314. Mexico Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2015-2020)
  • Table 315. Mexico Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2015-2020)
  • Table 316. Mexico Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2015-2020)
  • Table 317. Neisseria Gonorrhoeae Infections Treatment: by Type(USD/Units)
  • Table 318. Company Basic Information, Sales Area and Its Competitors
  • Table 319. Company Basic Information, Sales Area and Its Competitors
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Neisseria Gonorrhoeae Infections Treatment: by Type(USD Million)
  • Table 328. Neisseria Gonorrhoeae Infections Treatment Cribrostatin-6  , by Region USD Million (2021-2026)
  • Table 329. Neisseria Gonorrhoeae Infections Treatment Dalbavancin  , by Region USD Million (2021-2026)
  • Table 330. Neisseria Gonorrhoeae Infections Treatment Debio-1453  , by Region USD Million (2021-2026)
  • Table 331. Neisseria Gonorrhoeae Infections Treatment Gepotidacin Mesylate  , by Region USD Million (2021-2026)
  • Table 332. Neisseria Gonorrhoeae Infections Treatment Others , by Region USD Million (2021-2026)
  • Table 333. Neisseria Gonorrhoeae Infections Treatment: by Patient Type(USD Million)
  • Table 334. Neisseria Gonorrhoeae Infections Treatment Gonorrhea treatment in adults , by Region USD Million (2021-2026)
  • Table 335. Neisseria Gonorrhoeae Infections Treatment Gonorrhea treatment for partners , by Region USD Million (2021-2026)
  • Table 336. Neisseria Gonorrhoeae Infections Treatment Gonorrhea treatment for babies , by Region USD Million (2021-2026)
  • Table 337. Neisseria Gonorrhoeae Infections Treatment: by Drugs(USD Million)
  • Table 338. Neisseria Gonorrhoeae Infections Treatment Erythromycin , by Region USD Million (2021-2026)
  • Table 339. Neisseria Gonorrhoeae Infections Treatment Clarithromycin , by Region USD Million (2021-2026)
  • Table 340. Neisseria Gonorrhoeae Infections Treatment Azithromycin , by Region USD Million (2021-2026)
  • Table 341. Neisseria Gonorrhoeae Infections Treatment Roxithromycin , by Region USD Million (2021-2026)
  • Table 342. Neisseria Gonorrhoeae Infections Treatment Others , by Region USD Million (2021-2026)
  • Table 343. Neisseria Gonorrhoeae Infections Treatment: by Adminstration(USD Million)
  • Table 344. Neisseria Gonorrhoeae Infections Treatment Oral , by Region USD Million (2021-2026)
  • Table 345. Neisseria Gonorrhoeae Infections Treatment Injectable , by Region USD Million (2021-2026)
  • Table 346. Neisseria Gonorrhoeae Infections Treatment: by End User(USD Million)
  • Table 347. Neisseria Gonorrhoeae Infections Treatment Clinic  , by Region USD Million (2021-2026)
  • Table 348. Neisseria Gonorrhoeae Infections Treatment Hospital  , by Region USD Million (2021-2026)
  • Table 349. Neisseria Gonorrhoeae Infections Treatment Others , by Region USD Million (2021-2026)
  • Table 350. South America Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2021-2026)
  • Table 351. South America Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 352. South America Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 353. South America Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 354. South America Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 355. South America Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 356. Brazil Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 357. Brazil Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 358. Brazil Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 359. Brazil Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 360. Brazil Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 361. Argentina Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 362. Argentina Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 363. Argentina Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 364. Argentina Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 365. Argentina Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 366. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 367. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 368. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 369. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 370. Rest of South America Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 371. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2021-2026)
  • Table 372. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 373. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 374. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 375. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 376. Asia Pacific Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 377. China Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 378. China Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 379. China Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 380. China Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 381. China Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 382. Japan Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 383. Japan Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 384. Japan Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 385. Japan Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 386. Japan Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 387. India Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 388. India Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 389. India Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 390. India Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 391. India Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 392. South Korea Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 393. South Korea Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 394. South Korea Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 395. South Korea Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 396. South Korea Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 397. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 398. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 399. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 400. Taiwan Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 401. Taiwan Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 402. Australia Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 403. Australia Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 404. Australia Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 405. Australia Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 406. Australia Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 407. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 408. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 409. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 410. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 411. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 412. Europe Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2021-2026)
  • Table 413. Europe Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 414. Europe Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 415. Europe Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 416. Europe Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 417. Europe Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 418. Germany Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 419. Germany Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 420. Germany Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 421. Germany Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 422. Germany Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 423. France Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 424. France Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 425. France Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 426. France Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 427. France Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 428. Italy Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 429. Italy Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 430. Italy Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 431. Italy Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 432. Italy Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 433. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 434. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 435. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 436. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 437. United Kingdom Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 438. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 439. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 440. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 441. Netherlands Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 442. Netherlands Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 443. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 444. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 445. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 446. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 447. Rest of Europe Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 448. MEA Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2021-2026)
  • Table 449. MEA Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 450. MEA Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 451. MEA Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 452. MEA Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 453. MEA Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 454. Middle East Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 455. Middle East Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 456. Middle East Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 457. Middle East Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 458. Middle East Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 459. Africa Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 460. Africa Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 461. Africa Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 462. Africa Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 463. Africa Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 464. North America Neisseria Gonorrhoeae Infections Treatment, by Country USD Million (2021-2026)
  • Table 465. North America Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 466. North America Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 467. North America Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 468. North America Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 469. North America Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 470. United States Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 471. United States Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 472. United States Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 473. United States Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 474. United States Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 475. Canada Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 476. Canada Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 477. Canada Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 478. Canada Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 479. Canada Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 480. Mexico Neisseria Gonorrhoeae Infections Treatment, by Type USD Million (2021-2026)
  • Table 481. Mexico Neisseria Gonorrhoeae Infections Treatment, by Patient Type USD Million (2021-2026)
  • Table 482. Mexico Neisseria Gonorrhoeae Infections Treatment, by Drugs USD Million (2021-2026)
  • Table 483. Mexico Neisseria Gonorrhoeae Infections Treatment, by Adminstration USD Million (2021-2026)
  • Table 484. Mexico Neisseria Gonorrhoeae Infections Treatment, by End User USD Million (2021-2026)
  • Table 485. Neisseria Gonorrhoeae Infections Treatment Sales: by Type(K Tons)
  • Table 486. Neisseria Gonorrhoeae Infections Treatment Sales Cribrostatin-6  , by Region K Tons (2021-2026)
  • Table 487. Neisseria Gonorrhoeae Infections Treatment Sales Dalbavancin  , by Region K Tons (2021-2026)
  • Table 488. Neisseria Gonorrhoeae Infections Treatment Sales Debio-1453  , by Region K Tons (2021-2026)
  • Table 489. Neisseria Gonorrhoeae Infections Treatment Sales Gepotidacin Mesylate  , by Region K Tons (2021-2026)
  • Table 490. Neisseria Gonorrhoeae Infections Treatment Sales Others , by Region K Tons (2021-2026)
  • Table 491. Neisseria Gonorrhoeae Infections Treatment Sales: by Patient Type(K Tons)
  • Table 492. Neisseria Gonorrhoeae Infections Treatment Sales Gonorrhea treatment in adults , by Region K Tons (2021-2026)
  • Table 493. Neisseria Gonorrhoeae Infections Treatment Sales Gonorrhea treatment for partners , by Region K Tons (2021-2026)
  • Table 494. Neisseria Gonorrhoeae Infections Treatment Sales Gonorrhea treatment for babies , by Region K Tons (2021-2026)
  • Table 495. Neisseria Gonorrhoeae Infections Treatment Sales: by Drugs(K Tons)
  • Table 496. Neisseria Gonorrhoeae Infections Treatment Sales Erythromycin , by Region K Tons (2021-2026)
  • Table 497. Neisseria Gonorrhoeae Infections Treatment Sales Clarithromycin , by Region K Tons (2021-2026)
  • Table 498. Neisseria Gonorrhoeae Infections Treatment Sales Azithromycin , by Region K Tons (2021-2026)
  • Table 499. Neisseria Gonorrhoeae Infections Treatment Sales Roxithromycin , by Region K Tons (2021-2026)
  • Table 500. Neisseria Gonorrhoeae Infections Treatment Sales Others , by Region K Tons (2021-2026)
  • Table 501. Neisseria Gonorrhoeae Infections Treatment Sales: by Adminstration(K Tons)
  • Table 502. Neisseria Gonorrhoeae Infections Treatment Sales Oral , by Region K Tons (2021-2026)
  • Table 503. Neisseria Gonorrhoeae Infections Treatment Sales Injectable , by Region K Tons (2021-2026)
  • Table 504. Neisseria Gonorrhoeae Infections Treatment Sales: by End User(K Tons)
  • Table 505. Neisseria Gonorrhoeae Infections Treatment Sales Clinic  , by Region K Tons (2021-2026)
  • Table 506. Neisseria Gonorrhoeae Infections Treatment Sales Hospital  , by Region K Tons (2021-2026)
  • Table 507. Neisseria Gonorrhoeae Infections Treatment Sales Others , by Region K Tons (2021-2026)
  • Table 508. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2021-2026)
  • Table 509. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 510. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 511. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 512. South America Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 513. South America Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 514. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 515. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 516. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 517. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 518. Brazil Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 519. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 520. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 521. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 522. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 523. Argentina Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 524. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 525. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 526. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 527. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 528. Rest of South America Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 529. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2021-2026)
  • Table 530. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 531. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 532. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 533. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 534. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 535. China Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 536. China Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 537. China Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 538. China Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 539. China Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 540. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 541. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 542. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 543. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 544. Japan Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 545. India Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 546. India Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 547. India Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 548. India Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 549. India Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 550. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 551. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 552. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 553. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 554. South Korea Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 555. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 556. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 557. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 558. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 559. Taiwan Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 560. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 561. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 562. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 563. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 564. Australia Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 565. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 566. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 567. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 568. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 569. Rest of Asia-Pacific Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 570. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Country K Tons (2021-2026)
  • Table 571. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 572. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 573. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 574. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 575. Europe Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 576. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 577. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 578. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 579. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 580. Germany Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 581. France Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 582. France Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 583. France Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 584. France Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 585. France Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 586. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 587. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 588. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 589. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 590. Italy Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 591. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 592. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 593. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 594. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 595. United Kingdom Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
  • Table 596. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Type K Tons (2021-2026)
  • Table 597. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Patient Type K Tons (2021-2026)
  • Table 598. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Drugs K Tons (2021-2026)
  • Table 599. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by Adminstration K Tons (2021-2026)
  • Table 600. Netherlands Neisseria Gonorrhoeae Infections Treatment Sales, by End User K Tons (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neisseria Gonorrhoeae Infections Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Neisseria Gonorrhoeae Infections Treatment: by Patient Type USD Million (2015-2020)
  • Figure 6. Global Neisseria Gonorrhoeae Infections Treatment: by Drugs USD Million (2015-2020)
  • Figure 7. Global Neisseria Gonorrhoeae Infections Treatment: by Adminstration USD Million (2015-2020)
  • Figure 8. Global Neisseria Gonorrhoeae Infections Treatment: by End User USD Million (2015-2020)
  • Figure 9. South America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 10. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 11. Europe Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 12. MEA Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 13. North America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 14. Global Neisseria Gonorrhoeae Infections Treatment: by Type K Tons (2015-2020)
  • Figure 15. Global Neisseria Gonorrhoeae Infections Treatment: by Patient Type K Tons (2015-2020)
  • Figure 16. Global Neisseria Gonorrhoeae Infections Treatment: by Drugs K Tons (2015-2020)
  • Figure 17. Global Neisseria Gonorrhoeae Infections Treatment: by Adminstration K Tons (2015-2020)
  • Figure 18. Global Neisseria Gonorrhoeae Infections Treatment: by End User K Tons (2015-2020)
  • Figure 19. South America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 20. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 21. Europe Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 22. MEA Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 23. North America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 24. Global Neisseria Gonorrhoeae Infections Treatment: by Type USD/Units (2015-2020)
  • Figure 25. Global Neisseria Gonorrhoeae Infections Treatment share by Players 2020 (%)
  • Figure 26. Global Neisseria Gonorrhoeae Infections Treatment share by Players (Top 3) 2020(%)
  • Figure 27. Global Neisseria Gonorrhoeae Infections Treatment share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Allergan Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Allergan Plc (Ireland) Revenue: by Geography 2020
  • Figure 31. BioDiem Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 32. BioDiem Ltd (Australia) Revenue: by Geography 2020
  • Figure 33. Debiopharm International SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Debiopharm International SA (Switzerland) Revenue: by Geography 2020
  • Figure 35. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 37. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 39. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Paratek Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Paratek Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Recce Pty Ltd (Australia) Revenue, Net Income and Gross profit
  • Figure 44. Recce Pty Ltd (Australia) Revenue: by Geography 2020
  • Figure 45. Redx Pharma Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. Redx Pharma Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 47. Global Neisseria Gonorrhoeae Infections Treatment: by Type USD Million (2021-2026)
  • Figure 48. Global Neisseria Gonorrhoeae Infections Treatment: by Patient Type USD Million (2021-2026)
  • Figure 49. Global Neisseria Gonorrhoeae Infections Treatment: by Drugs USD Million (2021-2026)
  • Figure 50. Global Neisseria Gonorrhoeae Infections Treatment: by Adminstration USD Million (2021-2026)
  • Figure 51. Global Neisseria Gonorrhoeae Infections Treatment: by End User USD Million (2021-2026)
  • Figure 52. South America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 53. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 54. Europe Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 55. MEA Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 56. North America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 57. Global Neisseria Gonorrhoeae Infections Treatment: by Type K Tons (2021-2026)
  • Figure 58. Global Neisseria Gonorrhoeae Infections Treatment: by Patient Type K Tons (2021-2026)
  • Figure 59. Global Neisseria Gonorrhoeae Infections Treatment: by Drugs K Tons (2021-2026)
  • Figure 60. Global Neisseria Gonorrhoeae Infections Treatment: by Adminstration K Tons (2021-2026)
  • Figure 61. Global Neisseria Gonorrhoeae Infections Treatment: by End User K Tons (2021-2026)
  • Figure 62. South America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 63. Asia Pacific Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 64. Europe Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 65. MEA Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 66. North America Neisseria Gonorrhoeae Infections Treatment Share (%), by Country
  • Figure 67. Global Neisseria Gonorrhoeae Infections Treatment: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Allergan Plc (Ireland)
  • BioDiem Ltd (Australia)
  • Debiopharm International SA (Switzerland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Paratek Pharmaceuticals, Inc. (United States)
  • Recce Pty Ltd (Australia)
  • Redx Pharma Plc (United Kingdom)
Additional players considered in the study are as follows:
Sarepta Therapeutics, Inc. (United States) , Sumitomo Dainippon Pharma Co., Ltd (Japan)
Select User Access Type

Key Highlights of Report


Dec 2020 246 Pages 80 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neisseria Gonorrhoeae Infections Treatment Quantitative research analysis
Global Neisseria Gonorrhoeae Infections Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing gonorrhea prevalence " is seen as one of major growth factors of Neisseria Gonorrhoeae Infections Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Neisseria Gonorrhoeae Infections Treatment Report?

Have a Query? Click Here

Other Related Reports

Radiation Injury Drugs Comprehensive Study by Type (Aerosurf, BMX-001, C-2E2, C-2E5, Des-Asp Angiotensin 1, DG-3, Others), Application (Solar and Cosmic Radiation, Man-Made Radiation (Computed Tomogr...
$ 3750
Calcium Acetate Tablet Comprehensive Study by Sales Channel (Online, Offline), Packaging (Plastic Strip, Box, Small Bottle, Other), End User (Hospitals, Clinics, Dialysis Centres, Others) Players and...
$ 3500
Antibacterial Drug Resistance Comprehensive Study by Drugs (Antibiotics, Antifungals, Antivirals, Antimalarials, Anthelmintics, Others), Disease Type (Complicated Urinary Tract Infection (cUTI), Comp...
$ 3750
Pharma Excipients Comprehensive Study by Type (Organic Chemicals (Carbohyrates, Petrochemicals), Inorganic Chemicals (Calcium Phosphates, Calcium Carbonate, Calcium Sulfate, Halites, Metallic Oxides)...
$ 3650
Tocotrienol Comprehensive Study by Type (Alpha, Beta, Gamma, Delta), Application (Breast Cancer, Hypertrophic Scars, Fracture Healing, NAFLD, Familial Dysautonomia, Chronic Kidney Disease, Others), D...
$ 3650
Hemostatic Agents Comprehensive Study by Type (Passive Agents (Collagen, Cellulose, Gelatin, Polysaccharide hemospheres), Active Agents (Thrombin, FloSeal, Sealants), Newer Hemostatic Agents (Chitos...
$ 3750